SELVA: A Phase 3 Study with a Fit-For-Purpose Primary Endpoint Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Presenter: Joyce Teng, M.D., Ph.D.; Professor of Dermatology and Pediatrics, Stanford University
QTORINTM rapamycin 3.9% anhydrous gel: A Novel, Dermal-Targeted Topical mTOR Inhibitor in Phase 3 for Treatment of Microcystic Lymphatic Malformations
Presenter: Jeff Martini, Ph.D., Chief Scientific Officer, Palvella Therapeutics
Doux J. Barriers and Opportunities: A View Across the Developmental Divide. Journal of Investigative Dermatology (2015) 135, 2143–2144.
Licholai G. Rare Dermatology: Orphan Disease Drug Development Opportunities and Challenges. Dermatology Summit (2019).
Hammill AM, et al., Sirolimus for the treatment of complicated vascular anomalies in children. Pediatric Blood and Cancer (2011).
Adams DM, et al., Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics (2016).
Canaud G, et al., A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet Journal of Rare Diseases (2021).
Carroll S, et. al., Annual prevalence estimation of lymphatic malformation with a cutaneous component: observational study of a national representative sample of physicians. Orphanet Journal of Rare Diseases (2022).
Teng JMC, et. al., Sirolimus in the Treatment of Microcystic Lymphatic Malformations: A Systematic Review. Lymphatic Research and Biology (2022).
